Vision

HEALTH
&WEALTH
EVERGREEN

ATEM Capital is a global healthcare investment firm, headquartered in New York, which provides investor-friendly financial products for sizeable mid- to long-term finance via its established access to landmark deal flow and industrial quality expertise in Life Sciences.

EVERGREEN
IS THE NEW
BLACK

ATEM manages Health Square Fund with an evergreen structure, which is considered to be a natural evolution in the Life Sciences investment space — favorable to limited partners and entrepreneurs alike. This modern approach is central to superior compounding returns, maximum value, flexibility and transparency to wealth providers as well as continuous support to healthcare entrepreneurs.

Why invest into healthcare?

Put Your
money to
life

Fundamental factors are fueling steady growth of the healthcare markets worldwide despite any financial vulnerabilities, with latest years setting a new sustainable record.

Sound
Fundamentals

Rapid population increase in developing countries as well as aging and chronic diseases in the developed world are fundamentally supporting decades’ long growth of the global demand for healthcare

Government and people’s spend on healthcare is constantly increasing both in absolute and relative terms despite financial vulnerabilities, thus creating stable multibillion markets and attractive investment opportunities

Robust
Markets

2014 continued the row of successful years for biotech IPOs setting a new record since a decade

M&A markets continue to be strong with healthcare companies increasingly driving their revenue growth through acquisitions

INVESTMENT Thesis

LIFE
MATTERS.
MOST
&ALWAYS

Superior drug or technology with strong IP protection targeting vast reimbursed and out-of-pocket markets becomes a must-have asset for larger industry players and yields healthy returns to investors

INVESTMENT Themes

Our
Sweet
Spots

70% Biotechnology /
Pharmaceuticals
30% Devices /
Diagnostics

20% Scientific
Home-Runs

Early-stage breakthrough science managed by high-caliber serial entrepreneurs with unmatched track-record of success

50% Blockbusters

Late-stage assets backed by healthcare specialists with human proof of concept and blockbuster potential

30% De-Risked Medical Devices & Diagnostics

Growth funding and “Last Money In” investments to support final approval steps, launch and international marketing efforts

Focus
Areas

The ATEM word (from Old English “æþm”, Greek “asthma”, German “Atem”) stands for “breath” and “spirit” – part and parcel of human life. Our investment strategy is strictly patient-centric and based on the notion that critical change to life creates distinct value. We are laser-focused on life-saving, life-changing and pregnancy-related technologies, viable and relevant to many in the observable future.

ONCOLOGY

Therapies with cure ambition, novel mechanisms of action and delivery as well as human data and signs of efficacy. New generation diagnostics technologies

CARDIO-VASCULAR

Therapies and technologies which can save lives with strong human data and manageable regulatory path

ANTI-INFECTIVES

New efficient therapies and technologies at all stages, which cure, overcome resistance, shrink time to cure or prevent the disease altogether

CNS / PAIN

Therapies that let people enjoy their life experiences, with human proof-of-concept, understood mechanism of action and clear regulatory path

WOMEN'S HEALTH

Wide range of therapies and technologies at all stages, which help women give birth to healthy children

We leave
no stone
unturned

Boston 30%
New York 5%
Vancouver 2%
Montreal 2%
San Francisco 25%
San Diego 10%
Chicago 5%
Amsterdam 4%
London 4%
Berlin 4%
Basel 4%
Paris 4%

We are diligently monitoring over 30,000 biotech and pharma development projects worldwide via numerous professional databases and our proprietary sources and in-house Big Data instruments. We have exceptional visibility into the following universes:

  • portfolios of like-minded investment funds in the US and Western Europe
  • companies listed on major stock exchanges with market capitalization under US$300 million
  • exclusive private projects founded by the serial entrepreneurs within our carefully selected and cultivated network
Why ATEM?

We are
game
changers

Our mission is straightforward – we provide efficient access to one of the most exciting and private asset class of Life Sciences innovations with previously unattainable combination of professionalism, accessibility and transparency

Maximum
value to
investors

We believe that our innovative evergreen investment model is complimentary to the traditional VC funds and benefits wealth providers with shorter investment horizons and stricter requirements to control and costs

FUNDAMENTAL VALUE

  • Access to landmark deal flow of major like-minded US and Western Europe VC firms as well as exclusive private projects of successful serial entrepreneurs
  • Real-time insights from most connected Advisory Board and Scientific Advisory Board into investment opportunities and Big Pharma needs
  • Industrial approach to decision-making process and risk management

BEST INVESTOR TERMS

  • Compounding returns
  • Accessible levels of participations

FOR LARGER INVESTORS:

  • Best terms on Management Fees
  • Direct co-investments

FLEXIBILITY & TRANSPARENCY

  • Viable lock-up period
  • Annual Audit by a Big-4 company under GAAP
  • ‘Quant’ approach to risk management

FOR LARGER INVESTORS:

  • Quarterly re-evaluation of portfolio by an independent certified appraiser
  • Live extracts of the assets standing upon request

Minimum
disruption to
entrepreneurs
& co-investors

We trust the entrepreneurs and the teams we support on both personal and professional levels and seek to become ideal investor/co-investor and strengthen our long-standing relations

NO STRINGS ATTACHED

We understand and support your focus on your business and your core activities. We would be happy to advise you on Emerging Market strategies where we have an edge, but would not require you to pursue those

TRANSPARENT DECISION-MAKING PROCESS

We value your time as much as we value ours and provide early feedback to you straight at the first meeting and communicate the probability of investment within few weeks after we get access to your data

COMMITMENT IN CHALLENGING MOMENTS

Our evergreen structure enables us to support you through the relevant value creation cycle. We do not have vintage or cross-funding issues and work well in a mix with traditional funds for value protection

Team

It is all about the people

Our international team combines big picture perspective and long-term technology view with decades of experience in investment, science, operations, IP & legal and portfolio risk management. it comprises high-caliber entrepreneurs, VC veterans & seasoned industry professionals

Media Center

Look
into the

press

20 January Healthcare restructuring pressures drug developers

Anton Gopka speaks at Biotech Showcase Conference 2014 on international perspectives of healthcare markets

26 August Watch Marinus Ring The NASDAQ Opening Bell!

Chris Cashman, Marinus Pharmaceuticals CEO, and the whole team ringing the NASDAQ Opening Bell

26 August CNBC Coverage of Marinus IPO

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Rings The NASDAQ Stock Market Opening Bell

10 January Straight From Russia

Anton Gopka launches a series of posts on the Russian healthcare

15 January RMI’s Gopka Seeks Revolutionary Science, Industry Relationships

Fun article on one day of a Venture Capitalist life during the JP Morgan conference heat

17 February Interview with Anton Gopka (In Russian)

Anton Gopka's interview with the readers of the major Russian pharma specialist press

Let’s Talk

Email us at
info@atemcap.com
or request callback to #
Message has been sent
and follow us